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Abstract 
 
Introduction: Autoimmunity against pancreatic beta-cells leads to an absolute shortage of the 
hormone insulin, resulting in hyperglycemia and the onset of type 1 diabetes (T1D). Proteomic 
approaches have been used to elucidate the mechanisms of beta-cell dysfunction and death.  
Areas covered: In the present review, we discuss new insights in the beta-cell proteome that 
have contributed to better insights in the role of the beta-cell in T1D. Techniques, such as 2D-
DIGE and MALDI imaging, together with new approaches for sample preparation, including 
laser capture microdissection and immunopeptidomics, have resulted in novel mechanistic 
insights in the pathogenesis of T1D.  We describe how proteomic studies in beta-cell lines as 
well as isolated islets from animal models and humans have discovered intracellular signaling 
pathways leading to beta-cell destruction, the generation of neo-antigens through post-
translational modifications of beta-cell antigens as well as better biomarkers of disease 
progression.   
Expert commentary: Proteomics has contributed to the discovery of beta-cell neo-
autoantigen generation through posttranslational modifications, hybrid insulin peptide 
formation and the generation of defective ribosomal gene products. These concepts are 
revolutionizing our insights in the pathogenesis of T1D, acknowledging a central role for the 
beta-cell in its own destruction.    
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1. Introduction 
Type 1 diabetes (T1D) is chronic autoimmune disease in which the immune system destroys 
the insulin-producing beta-cells, a process called insulitis [1]. A model explaining the 
progressive development of T1D in different phases was first described by George Eisenbarth 
in 1986 [2]. He proposed that the combination of genetic predisposition and unknown triggers 
initiate an autoimmune reaction against the beta-cells, leading to dysfunction and 
destruction. Whereas for a long time it was believed that the immune system was the only 
culprit in T1D, several investigators, amongst which Botazzo, launched the idea that the beta-
cell may not be an innocent victim but actively participates in its own destruction, a theory 
that is widely accepted and proven nowadays [3-6].  
A generally accepted hypothesis for development of T1D suggests that aspecific 
inflammation, caused for instance by a viral infection, could be the first trigger initiating T1D. 
Such inflammation can affect the beta-cells by activation of Nuclear factor-kappa-B (NF-κB) 
and Interferon regulatory factor 3 (IRF3), resulting in the release of pro-inflammatory 
cytokines, such as interferon-α (IFN-α) and IFN-β, which in turn will activate Signal transducer 
and activator of transcription 1 (STAT1). Subsequently, this will lead to upregulation of 
antigen presenting MHC-I molecules on the beta-cell surface and secretion of chemokines, 
such as chemokine (C-C motif) ligand 3 (CCL3), CCL4 and C-X-C motif chemokine ligand 10 
(CXCL10), which are able to attract more innate and adaptive immune cells to the islets [7,8]. 
Prolonged exposure of beta-cells to inflammation is known to induce oxidative and 
endoplasmic reticulum (ER) stress, associated with translational infidelity, alternative splicing, 
protein misfolding and the generation of post-translational modifications (PTMs) of proteins 
[9-11]. The unfolded protein response (UPR) will be activated, but at a point where this UPR 
fails to recover the cells from ER stress, apoptosis will be induced [12].  Such apoptotic beta-
cells are cleared by antigen presenting cells (APCs), like macrophages and dendritic cells (DCs), 
which present beta-cell antigen-derived peptides on their cell surface in and the context of 
MHC-II molecules. In addition to peptides processed in these APCs, naturally processed beta-
cell peptides, present in the ER due to degradation of proteins, will also be presented in the 
context of MHC-I on the beta-cells themselves [13].  
When the beta-cell antigens in MHC-II molecules of APC are recognized by CD4+ T-cells, they 
will become activated effector T-cells which in turn stimulate the maturation of CD8+ T-cells 
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into cytotoxic T-cells by production of pro-inflammatory cytokines such as interleukin 2 (IL-2). 
These cytotoxic T-cells can recognize beta-cell antigens presented by MHC-I molecules on the 
beta-cell surface, resulting in granzyme- and perforin-mediated beta-cell death [14]. During 
the development of insulitis, beta-cells and immune cells are engaged in a dialogue. Activated 
T-cells, macrophages and Natural Killer (NK) cells will produce cytokines such as IL-1β, IFN-γ 
and tumor necrosis factor α (TNFα) and beta-cells respond by producing more chemokines 
and stimulatory cytokines. If at this point the viscous circle is not halted, the road is open to 
the development of T1D [15]. 
Proteomic techniques and studies have contributed to a large extend to our understanding of 
T1D development leading to the above-described hypothesis, but also to the characterization 
of novel biomarkers and therapeutic applications. In this review we highlight the important 
role of proteomics to identify beta-cell targets as novel biomarkers and therapeutic 
applications in T1D. An overview is given on recent proteomic studies that further explored 
the active role of the beta-cell in the pathogenesis of T1D, as well as new approaches that are 
developing. 
 
2. Proteomics: the key towards a cure for T1D 
When the total functional beta-cell mass is reduced to 20-30%, hyperglycemia and associated 
glycosuria will arise, leading to the onset of overt diabetes. Nowadays, diagnosis is based on 
elevated random plasma glucose levels of >200 mg/dl, a fasting blood glucose of >126 mg/dl 
or glycated hemoglobin A1c (HbA1c) levels of >6.5%. At this point lifelong treatment by 
exogenous insulin administration is initiated in most of the patients. To enable the 
identification of individuals who are susceptible to T1D development at an early stage, 
screening tests can be performed. The strongest genetic predisposition for T1D is associated 
with certain HLA genes [16-18]. As such, 90% of the patients are carriers of either HLA-
DRB1*03 – DQB1*0201 (DR3 – DQ2) or DRB1*04 – DQB1*0302 (DR4 – DQ8) and 30% of them 
are even heterozygous for both (DR3/4) [19]. Compared to this, the prevalence in the general 
population is only 30%. Screening for this strong genetic risk factor indicates people with 
increases risk for T1D or other autoimmune diseases, but the sensitivity and specificity remain 
rather low. Therefore, the presence of autoantibodies in the circulation against beta-cell 
antigens such as insulin, glutamic acid decarboxylase of 65kDa (GAD65), tyrosine 
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phosphatase-like protein ICA152 (IA-2) and zinc transporter 8 (ZnT8) are used as more 
pathologically relevant targets to screen for in predisposed individuals. These antibodies are 
a consequence of the autoimmune reaction rather than being pathogenic themselves. 
However, during the period of progressive beta-cell destruction, in which normal blood 
glucose levels are still retained, autoantibodies already arise in the circulation indicating an 
ongoing autoimmune attack [20-24]. The number of different autoantibodies detectable is in 
direct relation to the relative risk to develop T1D in the future [20-22]. Whereas antibody 
based screening tests are much more predictive compared to genetic screening, the 
sensitivity still remains rather low, in particular in the general population.  
Several hurdles still exist on the path to the ultimate goal, namely preventing or finding an 
effective cure for T1D. First of all, there is a need for better biomarkers with improved 
sensitivity and specificity, to be able to identify people progressing towards diabetes at an 
early stage, when the functional beta-cell mass is still high. Second, we must be aware that 
T1D is a heterogeneous disease, as evidenced by for instance the wide spread in age at disease 
onset, differences in genetic susceptibility factors and the diversity in serum antibodies 
against beta-cell antigens between all patients. In addition, recently described stress-induced 
PTMs of beta-cell antigens occur and elicit auto reactivity only in a subset of patients. This 
diversity indicates that patients with T1D might have different underlying pathogeneses. 
Finding a good combination of biomarkers, which reflects the underlying pathogenesis of the 
disease, is of utmost importance to be able to stratify patients and develop more personalized 
therapies.   
 
3. Different proteomic approaches: strengths and limits 
Over the years, proteomic approaches have developed rapidly resulting in an increasing 
sensitivity, specificity and applicability on smaller samples. Depending on the experimental 
goal and sample type, multiple approaches can be considered, each with their own pros and 
cons. In the past, many studies have used the gel based 2-dimension difference gel 
electrophoresis (2D-DIGE), which has the advantage to investigate quantitative expression 
levels in a robust and rather simple way. However, relatively high amounts of protein are 
required, making this method inappropriate for the analysis of scarce samples. Also the fact 
that a certain pH range is analyzed implies that only a fraction of proteins are analyzed. 
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Furthermore, reproducibility is rather weak and since protein levels are investigated by 
fluorescent labeling, low abundant proteins are likely to be under the detection limit. Due to 
these limitations, mass spectrometry based techniques gain in popularity. In general, a 
distinction is made between top-down approaches, investigating whole proteins, and 
bottom-up approaches where peptides after protein digestion are analyzed. In both cases, 
mass-to-charge ratios (m/z) are determined and used for protein identification by database 
searches. Prior to mass analysis, samples undergo ionization, with matrix-assisted laser 
desorption ionization (MALDI) and electrospray ionization (ESI) being the main techniques. 
MALDI is a fast ionization technique, often used for samples with a low complexity. No prior 
separation step is required, opposed to for instance proteins extracted from 2D-gel spots. The 
ESI technique is used more commonly for ionization of complex samples, since this technique 
can easily be combined with liquid chromatography (LC) separation. Either ionization 
techniques were originally combined with time-of-flight (TOF) or TOF-TOF instruments. 
However, nowadays ESI is often used in combination with Orbitrap mass analyzers, which 
have significantly improved mass resolution and sensitivity [25,26]. Evidently, this goes along 
with an enormous increase in the amount of data generated, which requires suitable 
bioinformatics approaches to get interpretable knowledge out of these big-data lists.  
 
4. Why is the beta-cell attacked by the immune system in T1D?  
4.1. The beta-cell proteome in T1D 
In the early years of proteomic research in the field of diabetes, many investigators aimed to 
establish reference maps of the pancreas, islet and beta-cell proteome to get a better insight 
in the general protein expression profile [15]. A strong representation of molecular chaperons 
and proteins implicated in metabolic pathways emphasizes the role of beta-cells as secretory 
cells which are specialized in producing enormous amounts of insulin. This also raised interest 
in studying more in depth the secretory granule proteome, to investigate which other 
proteins are secreted simultaneously with insulin [15]. Whereas it remains a challenge to 
isolate pure secretory granules, most of these studies indicate that next to the well described 
secretory granule proteins such as proinsulin, chromogranin A (ChgA), secretogranins and 
vesicle-associated membrane proteins (VAMPs), also proteins previously known for being 
functional in mitochondria, lysosomes or ER such as chaperons, are present [27]. Although 
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this might partially reflect incomplete cellular fractionation, there are also arguments that at 
least some of these proteins play an active role in the secretory granules [15]. As several 
described T1D autoantigens are present in the secretory granules, knowledge of this protein 
repertoire provides more information about other proteins potentially at risk to become 
antigenic when beta-cells are for instance under stress.  
In order to investigate the islet and beta-cell proteome in the setting of T1D, ex-vivo exposure 
to IL-1β alone or in combination with other pro-inflammatory cytokines such as IFNγ and TNFα 
has been performed by many researchers. A synergistic action of these cytokines was 
observed, with major alterations in the beta-cell proteome, paralleled by induction of 
apoptosis and ER stress, as opposed to minor changes upon exposure to IL-1β alone. Recently 
it was described that human islets tend to be more resistant to cytokine-induced ER and 
oxidative stress as compared to rodent islets, and that TNF-α plays a more prominent role in 
the human setting [28].  
Although many of these studies had the same goal, namely to gain a better insight in beta-
cell function and dysfunction in T1D, by means of similar experiments, the results were often 
very different as displayed by the number of differentially expressed proteins as well as the 
protein identity or characterized pathways. This makes it very difficult to assign specific 
alterations to the effect of inflammation. An obvious explanation for the observed 
discrepancies is the fact that islets from different species, exposed to a slightly different 
combination and concentration of cytokines, were used. Moreover, the implication of distinct 
proteomic techniques and sample preparation methods should also not be underestimated.  
 
4.2. New insights in the beta-cell proteome in T1D  
A detailed overview of all proteomics studies in the field of T1D until early 2015 have been 
described in a previous review by our group [15]. In follow-up of this, we focus here on the 
most recent advances and novel technical approaches [Table 1].  
Although mostly preference is given to human islets, animal models are still indispensible for 
gaining mechanistic insights. To answer one of the main questions namely ‘Why is the beta-
cell attacked by the immune system in T1D?’ several studies aimed to identify predisposing 
genes and proteins in islets from pre-diabetic mice. Whereas the majority of these studies 
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focused on the role of the immune system by investigating islets from normoglycemic mice 
with already ongoing immune destruction [29-32], our group recently investigated whether 
islets from 2-3 week-old diabetes-prone NOD mice, i.e. before the occurrence of immune 
infiltration, differ from control mice, using a combination of 2D-DIGE and microarray. The 
most remarkable difference was the observation that NOD islet proteins are undergoing 
different PTMs, in particular citrullination by peptidyl arginine deiminase 2 (PAD2), compared 
to control mice. In addition, lower expression levels of proteins involved in correct folding, 
such as Protein disulfide isomerases (PDIA) 3, 4 and 6 make NOD islets more sensitive for 
protein misfolding, potentially leading to ER stress [33]. A 2D-DIGE-proteome comparison of 
NIT-1 beta-cells and αTC-1 alpha-cells confirmed that specifically the beta-cells are highly 
susceptible to ER and oxidative stress upon inflammation [34].  To clarify further downstream 
cytokine-mediated pathways, Rondas et al. investigated islets from STAT-1 knock-out (KO) 
mice by 2D-DIGE. These islets were mainly impaired in protein synthesis and processing and 
based on network analysis, small ubiquitin-related modifier 4 (SUMO4) was hypothesized as 
playing a central role in STAT-1 signaling [35].  
In order to investigate a specific pancreatic T1D signature, Burch et al. performed comparative 
proteome analysis from snap frozen human pancreatic tissue lysates from donors with T1D, 
T2D, autoantibody positive non-diabetic and autoantibody negative non-diabetic donors 
using LC-MS/MS (quadrupole-Orbitrap). In total 1149 proteins were identified of which 244 
proteins were differentially expressed, with 134 upregulated and 110 downregulated, in T1D 
compared to the non-diabetic donors. Functionally, these proteins were shown to be mainly 
involved in inflammation, metabolic regulation, and autoimmunity [36].  
The procedure to isolate pancreatic islets is associated with a certain amount of stress as such, 
which can result in proteomic alterations by itself. New techniques have been explored over 
the last years to overcome this drawback. Laser capture micro dissection (LCM) allows the 
isolation of specific type of cells from a tissue, such as the islets out of a pancreatic section. 
Recently, Zhang et al. [37] used this approach combined with nano LC-MS/MS to compare the 
proteomic profile of human islets and acinar tissue. This led to the identification of 1104 and 
706 proteins, respectively. A high proteomic overlap was observed between LCM islets and 
enzymatically isolated islets (984 proteins), but interestingly less stress-associated proteins 
and acinar proteins were identified using the first method. The relatively large proteome 
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coverage, together with good reproducibility and technical feasibility underscores the 
importance of LCM to become a more routinely used technique in future studies.  
MALDI imaging mass spectrometry (IMS) allows the highest possible cellular resolution 
achievable in shotgun proteomics nowadays. The minimal distortion of histological features 
during analysis allows a better understanding of biological processes [38]. In 2011, Green-
Mitchell et al. [39] used MALDI-IMS to identify a peak of 5812.85 Da, being highly expressed 
in islets from healthy subjects compared to T1D patients. In-situ reduction followed by 
alkylation was needed to allow identification of this protein peak as insulin. Since technical 
advances are developing rapidly, it is today already possible to detect higher molecular weight 
proteins up to 20 kDa using this sophisticated technology. 
Immunopeptidome analyses of beta-cells are performed in order to map the peptide 
repertoire presented in surface MHC-I molecules. These epitopes might be highly important 
for initiation or progression of autoimmunity since they are exposed to cytotoxic T-cells [40]. 
When investigating alterations in the peptidome of NIT-1 beta-cells upon exposure to IFNγ, 
Dudek et al. did not observe differences in peptide length or distribution of predicted binding 
affinities. However, significantly higher presentation of the immunodominant epitope of IGRP 
(206-214) upon cytokine exposure compared to a random endogenous peptide, was 
identified by multiple-reaction monitoring (MRM). On the other hand, the peptidome 
presented by immune cells is also important to gain a better understanding of the 
autoimmune process. Van Lummel et al. investigated the peptidome presented by immune 
cells, by pulsing dendritic cells with preproinsulin, GAD65 and IA-2. Subsequent analysis 
revealed that GAD65 peptides from previously identified immunogenic epitopes could be 
presented in HLA-DR3.  For IA-2, previously unknown immunogenic peptides from the 
extracellular domain were found to be presented in HLA-DR3 and DR4 and they elicited T-cell 
responses in T1D patients [41,42]. In addition, antigenic PPI and IA-2 were mainly presented 
in HLA-DQ8trans molecules, explaining the genetic risk of HLA-DQ2/8 heterozygosity [43]. 
More extensive studies are required to unravel the complex mechanism of peptide 
presentation, but it is presumed that stress-induced PTMs, in combination with genetic 
susceptibility, are also involved [44]. In general, peptidome studies contributed substantially 
to a better definition of consensus sequences for antigens presented in HLA molecules. This 
information has been implied in predictive bioinformatics approaches [40]. However, one 
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must keep in mind that immunogenic epitopes in autoimmunity are thought to have rather 
weak binding affinity for HLA molecules [45,46]. More extensive comparison of the beta-cell 
and thymus peptidome would be interesting to gain insight in the underlying causes of beta-
cell targeted autoimmunity [40,47]. Although no major general differences have been 
observed, a more directed approach to study some peptides in particular would be 
informative. Whereas, analysis of the immunopeptidome is also technically challenging, 
Caron et al. reviewed nicely the differences and advantages of several currently used MS/MS 
approaches [48].  
Recent studies have led to the hypothesis that T1D does not only involve the beta-cells in the 
pancreas. In addition to glucagon producing alpha-cells, several studies even reported 
abnormalities in function, as well as histology and anatomy, of the exocrine pancreas of T1D 
patients [49]. Proteomic analysis by tandem mass tag (TMT) and multidimensional LC-MS/MS 
of the exocrine pancreas revealed that 145 proteins of a total of 5357 proteins were 
differentially expressed in the exocrine pancreas of T1D patients compared to healthy 
subjects. These proteins were functionally related to the ubiquitin proteasome system, cell 
proliferation and apoptosis. Whereas this suggests the involvement of exocrine pancreatic 
cells in the pathogenesis of T1D, further investigation is needed to reveal if such findings are 
rather the consequence or cause of autoimmunity [50].  
 
4.3. Stress induced PTMs of beta-cell antigens: mechanism for break of tolerance 
It is estimated that 50-90% of all proteins in the human body are modified post-translationally 
and the majority of them are present in multiple isoforms. Modification can occur either by 
the attachment of chemical molecules to amino acids or by changing the chemical bond 
structure of proteins. Under physiological conditions, the main function of PTMs is the control 
of protein function, such as enzymatic activation, subcellular localization, stability, structure 
and interaction with other proteins or cells. While the total time needed for transcription and 
translation can take several hours, PTMs are able to activate or inactivate specific protein 
functions in a very rapid and dynamic way. Apart from this, activation of specific modifying 
enzymes as a result of cellular stress, such as tissue transglutaminases (tTG) and PADs, can 
lead to the generation of neo-epitopes. It is known from several autoimmune diseases, 
including T1D that such modifications can lead to a break of immune tolerance [Table 2]. 
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Several mechanisms can be responsible for this. At the peptide level, PTMs can modulate the 
affinity and positioning of peptides in the HLA binding groove. As such, it is known that certain 
diabetes susceptible HLA types preferentially present modified peptides, such as HLA-DR4 
and DR3 for citrullinated peptides and HLA-DQ2 and DQ8 for deamidated peptides [44]. At 
the protein level, PTMs might influence processing by proteases, resulting in an altered pool 
of peptides generated in stressed tissues such as the islets in T1D, as compared to the thymus. 
In addition, PTMs that affect the tertiary structure can result in exposure of internal epitopes 
at the outside of the protein, which could potentially lead to B-cell receptor recognition. 
The first modified antigen in T1D was described in 2005 by Mannering et al. They 
demonstrated a disulfide bond between cysteine A6 and A7 of a naturally processed peptide 
of the insulin A-chain (A1-13). This modification had no effect on the presentation by HLA-
DR4, but was shown to be crucial for recognition by CD4+ T-cell clones from a T1D donor and 
an insulin autoantibody positive donor at risk for T1D [51].  
More recently, Stadinski et al. [52] identified WE14, a naturally processed peptide from the 
secretory granule protein ChgA, as target antigen for diabetic T-cell clones in NOD mice. 
Although the WE14 peptide contains the WXRM amino acid motif, a mimotope sequence for 
activation of these T-cell clones, very high concentrations of the peptide were needed in vitro 
to activate T-cells. Moreover, the WE14 peptide could not be detected by MS in antigenic 
fractions, opposed to the detection of full length ChgA. Of interest, PTM of WE14 by 
enzymatic treatment with tTG resulted in increased stimulation of diabetic T-cell clones [53]. 
Separation of in vitro transglutaminated WE14 peptide on SDS-PAGE showed that aggregates 
were formed upon tTG exposure and fractionation by size exclusion chromatography, 
followed by co-culture of these fractions with diabetogenic T-cell clones revealed that both 
high and low molecular weight aggregates were the actual inducers of enhanced antigenicity. 
In follow-up of this study in mice, it was shown in humans that peripheral blood mononuclear 
cells (PBMCs) of recent onset T1D patients recognized WE14 in a dose dependent way and 
similar as for NOD T-cell clones, TGase treatment increased the T-cell response [54]. 
Furthermore, the pathogenic importance of ChgA as autoantigen was proven by protection 
of NOD mice deficient in ChgA against diabetes development [55]. In the same line, Van 
Lummel et al. [56] discovered that tTG modification of other T1D antigens enhanced their 
antigenicity, suggesting a more general role for this modification in T1D. They screened 
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known T1D antigen peptides with the tTG substrate motif (e.g. proinsulin, ZnT8, IA-2, GAD65, 
ICA69, phogrin and IGRP) for binding to the T1D-predisposing HLA-DQ8cis/trans molecule. 
Deamidation of 28 peptides was confirmed, but activated T-cells could only be detected 
against a deamidated peptide of proinsulin. Furthermore, recent onset T1D patients showed 
much higher levels of autoreactive T-cells recognizing this modified proinsulin peptide as 
compared to healthy controls, confirming its role as a pathogenic autoantigen. 
Marré et al. investigated the mechanism behind the presence of deamidated antigens in T1D 
and pointed to the importance of ER stress [44]. Exposure of mouse islets to chemical ER 
stress by thapsigargin (Tg) increased cytoplasmic Ca2+ levels, paralleled by elevated TGase 
activity and strong activation of the CD4+ diabetogenic BDC2.5 T-cell clone. The higher IFN-γ 
secretion by the T-cell clone against in vitro transglutaminated antigens further confirmed 
these findings. In addition to transglutamination, McGinty et al. showed the presence of 
antigenic GAD65 peptides modified by citrullination. Both modifications result in enhanced 
peptide binding to HLA-DR4 in vitro and recognition of these modified peptides by specific T-
cell clones of T1D patients. Furthermore, the presence of significantly higher amounts of 
these T-cells was observed in T1D patients compared to HLA-matched healthy controls [57]. 
Our group discovered that glucose-regulated protein 78 (GRP78) becomes citrullinated in INS-
1E beta-cells and mouse islets upon exposure to inflammatory stress. In addition, cytokines 
induced translocation of this molecular chaperon from the ER to the cell surface. As a result, 
citrullinated GRP78 was recognized as autoantigen in NOD mice, evidenced by the presence 
of autoantibodies and T-cell reactivity [58]. Furthermore, a very high expression of the 
citrullinating enzyme PAD2 was found in NOD islets compared to islets from control mice, 
further emphasizing the relevance of this gene for being the diabetes susceptibility gene in 
the Idd25 susceptibility locus [33,58,59].  
Next to these non-enzymatic and enzymatic modifications, Delong et al. described recently a 
novel mechanism of protein modification leading to a break of tolerance, namely the 
generation of hybrid insulin peptides (HIPs) [60,61]. They showed that CD4+ T-cell clones from 
NOD mice, but also CD4+ T-cells isolated from islets of T1D patients, show auto-reactivity 
against epitopes that were generated by covalent cross-linking of proinsulin peptides with 
other secretory granule peptides such as WE14 an IAPP. This kind of PTM, novel in 
autoimmune diseases, was already described as a mechanism for tumor antigen formation. 
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In this case, peptide hybrids are formed by trans-peptidation during proteasomal degradation 
[62-64]. In beta-cells, HIPs are presumed to be generated during proteolytic hydrolysis in 
secretory granules, where also naturally occurring cleavage products such as WE14 are 
formed [65].  
Whereas T-cell responses are mainly investigated in peripheral blood, Babon et al. studied 
the repertoire of islet-infiltrated T-cells.  CD4+ and CD8+ T-cell lines and clones were 
generated out of infiltrated islets from T1D patients and several of these clones reacted 
against a broad range of native beta-cell antigens. In addition, reactivity was also detected 
against PTM proteins such as citrullinated GRP78, citrullinated IAPP and HIPs, giving even 
more evidence for the importance of PTMs in loss of tolerance against beta-cell antigens [66].  
Kracht et al. recently discovered the expression of a defective ribosomal gene product (DRiP) 
of insulin, resulting from translation of an alternative open reading frame. Inflammatory and 
ER stress lead to increased expression levels of this DRiP protein. DRiP generation has been 
previously described in cancer cells, but is a novel mechanism for autoantigen generation in 
T1D. Autoreactive CD8+ T-cells that recognize this out-of-frame translational product of 
insulin were detected in blood of T1D patients and furthermore, these cells were capable of 
killing human beta-cells in vitro [67]. 
PTMs of beta-cell antigens are not only involved in activation of the cellular immune system. 
Patients with T1D also have higher levels of serum autoantibodies against modified epitopes, 
such as oxidized GAD65 [68,69], hydroxyl radical modified GAD65 [70], oxidized insulin 
[63,71], oxidized collagen II [72] and phosphorylated peripherin [73].  
To conclude, the important role that PTMs or alternative ribosomal products play in the 
pathogenesis of T1D became clear during the last 10 years. Since pro-insulin is the only beta-
cell specific antigen in T1D, it remained for long a mystery how autoimmunity against 
ubiquitously expressed proteins could lead to a specific attack of the beta-cells. The 
generation of PTMs under stress conditions in beta-cells, inducing structural changes of 
ubiquitously expressed proteins specifically in the beta-cell, can provide an explanation for 
this phenomenon.  
 
5. How to see beta-cell autoimmunity? The need for novel biomarkers 
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A high number of novel autoantigens or mechanisms implicated in the pathogenesis of T1D 
have been discovered during the last years. However, a major issue in the design of effective 
prevention and intervention studies is the lack of precise biomarkers to detect early stage of 
beta-cell decomposition or to use as surrogate endpoint in clinical studies. In 1998, the 
National Institutes of Health defined a biomarker as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to a therapeutic intervention” [74]. Importantly, 
biomarkers should be measurable in easily available body fluids such as blood, serum, plasma, 
urine or saliva. We refer to a previous review by our group for a detailed overview of 
serological biomarkers in T1D [15] and will focus here in particular on recent advances in the 
field. 
In most biomarker studies serum proteome analysis was performed. This is a challenging 
approach because of the wide dynamic range in abundance of proteins as well as the presence 
of high abundant serum proteins, such as albumin, transferrin and fibrinogen, all together 
accounting for 95% of the serum proteome. To overcome these issues, serum samples are 
often pre-processed, for instance by using hexa-peptide library beads or strong cation 
exchange (SCX) columns, to deplete these high abundant and at the same time enrich for the 
low abundant proteins [64]. Subsequent proteome analysis mainly includes shotgun 
proteomic techniques such as LC-MS/MS.  
Metz et al. [75] identified 24 serum proteins with altered expression in T1D patients that were 
associated with innate immunity, inflammatory response, blood coagulation and complement 
system. Later on, Zhang et al. [76] reported the validation of this study in samples from 
children aged 5-15 years using the LC-MS/MS accurate mass and time tag (AMT) method with 
selected reaction monitoring (SRM) [77]. Furthermore, this study showed that plasma 
protease C1 inhibitor and platelet basic protein achieved absolute sensitivity and specificity 
for classification of T1D samples.   
Although serum levels of proteins secreted by beta-cells are expected to be expressed at very 
low levels, Pepaj et al. succeeded in identifying transmembrane protein 27 (TMEM27), and 
showed a lower expression of this protein in  serum from T1D patients compared to healthy 
controls. Furthermore, they showed by SILAC combined with LC-MS that that this beta-cell 
protein, important for insulin secretion and beta-cell proliferation, was highly upregulated in 
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INS-1 cells upon 1,25dihydroxyvitamin D3 treatment [78]. Similarly, serum levels of insulin-
like growth factor 1 (IGF1) or IGF binding protein 3 (IGFBP3) were correlated to 
seroconversion and disease onset in genetically at risk children for T1D [79].  
Aiming to predict progression to T1D by measuring a minimal number of serum peptides, Von 
Toerne et al. compared the serum proteome of islet autoantibody positive and negative 
children from the BABYDIAB/BABYDIET cohort.  A significant enrichment of proteins involved 
in lipid metabolism was highlighted. Two peptides in particular, from apolipoprotein M and 
apolipoprotein C-IV, made it even possible to distinguish both groups [80]. Furthermore, 
Manjunatha et al. described that T1D patients have higher levels of irreversibly modified HDL 
proteins, such as amadori modification of ApoD and deamidation, compared to healthy 
subjects [81]. These modifications could explain the compromised function of HDL and the 
associated increased cardiovascular risk in T1D patients, however no difference was observed 
between patients with a good or poor glycemic control, suggesting that measuring serum 
levels of modified lipoproteins cannot be used as biomarker for cardiovascular risk in T1D 
patients. 
In addition to a broad MS analysis of the serum proteome, immunoproteomics is a more 
directed approach to evaluate ongoing autoimmunity against beta-cell antigens, by detecting 
autoantibodies in serum of T1D patients. One of the first studies was reported by Massa et 
al., who performed serological Proteome Analysis (SERPA) by separating beta-cell proteins on 
a 2D gel followed by blotting on a membrane and subsequent detection with serum of T1D 
patients who were positive against only one known beta-cell antigen [82]. Although several 
proteins such as carbonic anhydrase, PDI and tubulins were proposed as possible 
autoantigens, this has not been confirmed until now.  
Most recent studies make use of protein arrays, where immunoreactivity of serum is tested 
against a large number of proteins. LaBaer and Ramachandran developed a Nucleic Acid 
Programmable Protein Array (NAPPA) by spotting cDNA clones on a slide, leading to protein 
synthesis and capture [83]. Miersch et al. [84] used NAPPA to identify serum autoantibodies 
against 6,000 human proteins. They reported reactivity against 27 proteins in T1D patients, 
including ZnT8 and 26 novel antigens.  Further, validation with Luciferase Immuno-
Precipitation System (LIPS) assay verified the presence of autoantibodies to dual specificity 
tyrosine-phosphorylation-regulated kinase 2 (DYRK2) with 36% sensitivity at 98% specificity. 
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More recently, Bian et al. screened for the presence of autoantibodies against 10,000 human 
proteins, which led to the identification and validation of six novel T1D associated 
autoantibodies, against PTPRN2, MLH1, MTIF3, PPIL2, NUP50 and QRFPR, having a sensitivity 
of 16-27% and specificity of 95% [85]. In addition, they aimed to evaluate the association 
between T1D and viral infections by making use of customized arrays comprising 646 viral 
antigens. This indicated that T1D patients significantly recognized Epstein-Barr viral peptides, 
whereas previously mainly cockxackie viruses were attributed as being involved in T1D 
pathogenesis [72].  
Whereas most serum biomarkers are indicative for beta-cell autoimmunity, biomarkers that 
display evolving complications can be useful as well. Several proteomic analyses on urine 
samples of T1D and T2D patients have been performed in order to identify biomarkers that 
predict diabetic nephropathy. Most of these studies were performed by LC-MS/MS, which is 
known to have better peptide resolution and accuracy rates compared to MALDI-MS [86]. 
Caseiro et al. performed a proteome study by LC-MS/MS on urine of T1D patients with and 
without complications. Increased urinary levels of gelsolin and antithrombin-III were 
observed in all T1D patients, while ephrin type-B receptor 4 and vitamin K-dependent protein 
Z were identified as promising biomarkers for both retinopathy and nephropathy [87]. Suh et 
al. identified 1036 protein in urine samples by nano LC-MS/MS, with 50 of them showing a 
significant difference between T1D and healthy people. A distinctive observation was the high 
abundance of 13 lysosomal proteins and 15 proteins involved in vascular permeability and 
adhesion, pointing to hyperglycemia-associated inflammation in the kidney vasculature [88]. 
Although these studies are promising, further research is needed to reveal the clinical 
applicability of these proteins as biomarker. Meanwhile, the detection of albuminuria remains 
the golden standard to evaluate the development of nephropathy. 
 
6. Conclusion 
The search for a successful preventive strategy or an effective therapy to cure T1D engages 
the combined efforts of many scientists from different disciplines nowadays. Due to the 
multifactorial nature of this disease, collaboration and pooling of knowledge between 
different research domains such as immunology, endocrinology and molecular biology will be 
required. Proteomics plays a central role in this network, as an important tool to gain more 
17 
 
insight in the underlying pathogenesis of T1D by unraveling pathways associated with beta-
cell dysfunction. Furthermore, novel autoantigens or mechanisms to generate antigenicity, 
such as PTMs, HIPs and DRiPs, were discovered with the help of proteomic techniques. These 
will be important for further exploration as therapeutic targets. While this review focused on 
proteomics, the search for biomarkers is not restricted to this research field only. During 
recent years, many promising advances were made also in the identification of circulating 
microRNAs [89] and metabolomics [90]. In order to achieve sensitive, robust and personalized 
screening tests to predict the onset of T1D, therapeutic efficacy or the development of 
complications, it will be of utmost importance to combine knowledge from the fields of 
genetics, transcriptomics, proteomics and metabolomics. Advanced Systems Biology is 
expected to become of crucial importance in such meta-analyses. 
 
7. Expert commentary 
During the last 15 years, the importance of PTMs as a mechanism to induce a break of 
tolerance against self-antigens, became clear in many autoimmune diseases such as 
rheumatoid arthritis, systemic lupus erythematosus, colitis, multiple sclerosis and also type 1 
diabetes (T1D) [91]. Whereas in the past autoimmune disorders were rather considered as 
distinct diseases, over the years more and more evidence have pointed to common 
underlying pathogenic pathways. This is in particular the case for the generation of PTMs 
upon exposure of tissues or cells to inflammatory, ER or oxidative stress in different 
autoimmune diseases. The enzymes required for deamidation and citrullination, namely tTG 
and PAD, require high Ca2+ levels, which are reached under such stress situations [44]. But 
also HIPs [60] and DRiPs [67] are more abundantly identified under these circumstances. This 
concept may also explain why ubiquitously expressed proteins can be recognized as 
autoantigens, thereby leading to an autoimmune attack in a specifc target tissue, while other 
organs remain protected or unaffected. Furthermore, the observed differences in immune 
responses against modified beta-cell antigens between different patients, may be one of the 
important explanations for the heterogeneity of T1D. To our understanding, the new 
discoveries of the last years on newly described unconventional beta-cell antigens are 
probably just a tip of the iceberg.  
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Therefore, biomarkers that allow mapping of these differences in the underlying 
pathogenesis of T1D would be of utmost importance to stratify patients according to these 
characteristics. Furthermore, this would also be a starting point to approach therapies in a 
personalized way, for example by targeting tTG or PAD enzymes in patients where 
deamidation or citrullination were shown to be implicated in disease onset or progression. 
Although there is still a long way to go, step-by-step T1D research is bringing us closer to the 
development of personalized medicine. However, with current technologies, some limitations 
are still being faced that impede high throughput identification of more unconventional 
proteins or peptides. First of all, PTMs such as deamidation and citrullination result in a very 
small difference of only 0.984 Da in molecular weight compared to the native peptides. Even 
for the most sensitive mass analyzers, this difference is at the limit of detection. In addition, 
the prevalence of these modified peptides are typically extremely low abundant. At present 
the majority will probably not be identified or have such low confidence scores that they will 
be missed during analysis. Even though it is important that scores are considered strictly, it 
should be advised to be thoughtful when analyzing such data. Besides PTMs that occur by 
chemical amino acid modification, the difficulty to discover new HIPs and DRiPs is even more 
challenging since these sequences are unknown and currently not present in any database. 
As it is known that after MS/MS analysis, up to 50% of the peptides with a good score do not 
result in a satisfying identification, there is a reasonable chance that HIPs, DRiPs or even other 
alternative peptides are present and missed in current routine MS analyses. As nowadays, 
characterization of these peptides is only possible by a directed search for a specific peptide 
sequence, advances in mass spectrometry, development of new bioinformaticsespecially also 
in the search programs that would allow picking up such unconventionally processed or PTM 
modified proteins are warranted. This would mean a big step forward in unraveling the dark 
side of the proteome.  
 
8. Five year View 
Using human tissue is the desired path in proteome research of human diseases and is 
occurring more frequently in recent years. However, it still remains challenging in the field of 
T1D because of the limited availability of human islets. The development of highly sensitive 
techniques that only require small samples for analysis, major technical improvements in 
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detection tools and more efficient sample preparation, will lead to an increased use of human 
islet samples for research purposes in the coming years. In order to optimally utilize these 
precious samples, making them available for multiple studies and sharing and combining data 
more efficiently, several consortia have been established [92]. For example, the biobank 
“Network for Pancreatic Organ Donors with Diabetes” (nPOD) (http://www.jdrfnpod.org), 
launched in 2006 and supported by Juvenile Diabetes Research Foundation (JDRF), has the 
goal to distribute pancreases and other tissues from T1D autoantibody positive individuals 
[93]. Recently, INNODIA, a European initiative was launched, funded by the Innovative 
Medicines Initiative – Joint Undertaking (IMI-JU), involving academic and industry partners as 
well as foundations (JDRF and The Leona M. and Harry B. Helmsley charitable trust) 
(www.INNODIA.eu). This large network, also involving patients and their family members, is 
collecting samples from newly diagnosed T1D patients and first-degree relatives and is 
investigating novel biomarkers for disease progression.  
While until today, proteomics approaches are mainly applied in T1D fundamental and pre-
clinical research, the importance in the diagnostic clinical field is expected to grow. It remains 
challenging to obtain high quality protein samples from blood, but improved purification 
strategies are continuously being optimized.  Recently, multiple biomarkers that display the 
progressing development of T1D or associated complications were identified, of which the 
prognostic value is currently further confirmed. Remarkably, only a subpopulation of patients 
turns out to test positive for a specific biomarker. This further demonstrates the importance 
of personalized screening and diagnostic tests in order to apply suitable therapies to patients.  
 
Key Issues  
 Proteome profiling of islets, blood samples or other body fluids from T1D patients 
provides crucial information. 
 In addition to cell-lines, isolated islets of Langerhans from rats, mice and humans are 
widely used as a more physiological beta-cell source. A number of consortia and cohorts 
are launched to provide research samples such as islets, blood and serum from healthy 
and diabetic patients to researchers.    
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 Several studies used proteomics approaches to establish reference maps of the pancreas, 
islet and beta-cell proteome to get insight in the general expression profile.  
 The use of MALDI-IMS, LCM-based proteomics and immunopeptidome approaches in T1D 
studies helped in the identification of novel antigens.    
 The role of PTMs in the generation of neo-epitopes in T1D is highlighted. Also autoreactive 
T-cell responses towards HIPs and DRiPs showed the importance of unconventionally 
processed peptides in autoimmune diseases such as T1D.    
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Table 1. Overview of publications on beta-cell proteome and immunopeptidome studies  
Author Species Cell type Proteomics Technique Study Type Year Reference 
Crèvecoeur et al. Mus musculus Islets 2D-DIGE,MALDI-TOF/TOF Differential expression 2017 [33] 
Gorasia et al. Mus musculus Islets and NIT-1 and αTC-1 MALDI-TOF/TOF Differential expression 2015 [34] 
Rondas et al. Mus musculus Islets MALDI-TOF/TOF Differential expression 2015 [35] 
Burch et al. Homo sapiens Pancreas LC-MS/MS Reference Map 2015 [36] 
Zhang et al. Homo sapiens Pancreas LC-MS/MS Reference Map 2017 [37] 
Green-Mitchell et al. Homo sapiens Pancreas MALDI-MSI Reference Map 2011 [39] 
Dudek et al Mus musculus NIT-1   LC-MS/MS Immunopeptidome 2012 [40] 
van Lummel et al. Homo sapiens PBMC FT-MS Immunopeptidome 2016 [41] 
Peakman et al. Homo sapiens PBMC RP-HPLC, MALDI-TOF-MS Immunopeptidome 1999 [42] 
van Lummel et al. Homo sapiens PBMC FT-MS Immunopeptidome 2016 [43] 
Espinosa et al. Homo sapiens Thymus LC-MS/MS Immunopeptidome 2013 [47] 
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Table 2. Overview of publications on PTMs, HIPs and DRiPs in T1D 
 
Modification Type Protein/Peptide Year Author Reference 
Disulfide bond Insulin A chain 2005 Mannering et al. [51] 
Transglutamination WE14 Peptide of ChgA 2012 Delong et al. [53] 
Deamidation Proinsulin 2014 van Lummel et al. [56] 
Citrullination and Transglutamination GAD65 2014 McGinty et al. [57] 
Citrullination GRP78 2015 Rondas et al. [58] 
Citrullination and HIPs GRP78, IAPP 2016 Babon et al. [66] 
HIPs insulin-IAPP hybrid 2016 Wiles et al., Delong et al. [60, 61] 
DRIPs Insulin  2017 Kracht et al. [67] 
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